Biogen, Drug Prices & Medicare Spending
Biogen manufactures 6 drugs tracked by Medicare Part D with total spending of $5.4B.
Biogen Drugs, Ranked by Medicare Spending
| # | Drug | Generic Name | Cost/Claim | Generic? |
|---|---|---|---|---|
| 1 | Tecfidera | Dimethyl Fumarate | $4,103.00 | Yes |
| 2 | Tysabri | Natalizumab | $9,952.00 | Yes |
| 3 | Vumerity | Diroximel Fumarate | $4,710.00 | Yes |
| 4 | Spinraza | Nusinersen | $73,000.00 | Yes |
| 5 | Avonex | Interferon Beta-1a | $5,074.00 | Yes |
| 6 | Plegridy | Peginterferon Beta-1a | $6,161.00 | Yes |
Frequently Asked Questions
Biogen manufactures 6 drugs tracked by Medicare Part D, with total annual spending of $5.4B.
Spinraza (Nusinersen) is the most expensive at $73,000.00 per claim.
6 of 6 Biogen drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Source: CMS Medicare Part D Spending, 2026.